Kevin Clerkin is a Cardiology physician affiliated with NewYork–Presbyterian Hospital. OpenAlex indexes 290 publications with 5,213 citations (h-index 30).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
622 W 168th St
New York, NY 100323720
Telephone
212-305-4600Provider last certified this registry record 12 Mar 2024.
Industry payments
14 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Abbott LaboratoriesProgram year20254 payments
- Novartis Pharmaceuticals CorporationProgram year202523 payments
- CVRx, Inc.Program year20252 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
71.1%Beta blocker16.1%Metoprolol Succinate57%Carvedilol43%Part D≥44 patientsStatin12%Atorvastatin Calcium69%Rosuvastatin Calcium23%Pravastatin Sodium8%Part D<11 patients+ 13 more classes in this area
Metabolism & gastrointestinal
14.3%SGLT2 inhibitor7.4%Jardiance69%Farxiga31%Part D<11 patientsGLP-1 receptor agonist2.5%Ozempic100%Part D<11 patients+ 3 more classes in this area
Nervous system
4.2%Other nervous system drugs4.2%Vyndamax100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2020–2024 per NIH RePORTER. The latest:
- Identifying Novel Diagnostics and Mechanisms for Cardiac Allograft Vasculopathy
Columbia University Health Sciences
FY2024$170,351K23HL148528 - Identifying Novel Diagnostics and Mechanisms for Cardiac Allograft Vasculopathy
Columbia University Health Sciences
FY2023$170,366K23HL148528 - Identifying Novel Diagnostics and Mechanisms for Cardiac Allograft Vasculopathy
Columbia University Health Sciences
FY2022$170,380K23HL148528
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Lawrence Honig, MD, PhD
NewYork–Presbyterian Hospital
Nasser Altorki, MD
NewYork–Presbyterian Hospital
Michael Niederman, MD
NewYork–Presbyterian Hospital
Shunichi Homma, MD
NewYork–Presbyterian Hospital
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”